Latest Conference Articles

June 15th 2019, 8:17pm

European Hematology Association Congress

The combination of rigosertib and azacitidine demonstrated improved response rates over single-agent azacitidine in patients with higher-risk myelodysplastic syndrome, including patients naïve to a hypomethylating (HMA) agent and those who were refractory to HMAs.

June 15th 2019, 1:48am

European Hematology Association Congress

Naval G. Daver, MD, discusses the data that support quizartinib so far, ongoing investigations with this drug in the frontline setting, and the potential for the agent to be approved by the FDA.

June 15th 2019, 1:33am

European Hematology Association Congress

Frontline therapy with ibrutinib was successfully administered for more than 60 months in patients with chronic lymphocytic leukemia aged 65 years and older and provided improved progression-free and overall survival compared with chlorambucil.

June 14th 2019, 8:20pm

European Hematology Association Congress

Imetelstat treatment may allow patients with debilitating anemia due to myelodysplastic syndrome to remain transfusion-free for extended periods of time.

June 14th 2019, 7:32pm

European Hematology Association Congress

The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.

June 14th 2019, 5:36pm

European Hematology Association Congress

Simon Rule, MD, PhD, Plymouth University Medical School, discusses results of the phase III MabCute study evaluating subcutaneous rituximab as maintenance after standard subcutaneous rituximab induction and maintenance in patients who have relapsed or refractory indolent non-Hodgkin lymphoma.

June 14th 2019, 5:21pm

European Hematology Association Congress

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

June 7th 2019, 11:12pm

ASCO Annual Meeting

The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.

June 6th 2019, 12:27am

ASCO Annual Meeting

Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.

June 5th 2019, 9:33pm

ASCO Annual Meeting

Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.

June 5th 2019, 5:42am

ASCO Annual Meeting

Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.

June 5th 2019, 5:09am

ASCO Annual Meeting

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.

June 4th 2019, 11:56pm

ASCO Annual Meeting

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

June 4th 2019, 11:16pm

ASCO Annual Meeting

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

June 4th 2019, 10:56pm

ASCO Annual Meeting

The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.

June 4th 2019, 10:35pm

ASCO Annual Meeting

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

June 4th 2019, 5:20pm

ASCO Annual Meeting

A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.

June 4th 2019, 5:02am

ASCO Annual Meeting

Two new therapies are showing encouraging findings for patients with NSCLC with either RET rearranged or EGFR exon 20 insertions, raising hope that 2 hard-to-target driver alterations may soon have an associated targeted treatment.

June 4th 2019, 4:56am

ASCO Annual Meeting

Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

June 4th 2019, 4:48am

ASCO Annual Meeting

The investigational KRASG12C inhibitor AMG 510 achieved a 50% response rate in patients with KRASG12C-positive advanced non–small cell lung cancer, according to results from a phase I study presented at the 2019 ASCO Annual Meeting.